Invo Fertility, Inc. · NASDAQ:IVF
Invo Fertility — NAYA Biosciences — Investor Presentation (January 2025)
32 slides from Invo Fertility's investor presentation, Jan 7, 2025
Slide 1: NAYA Biosciences Corporate Presentation January 2025
NAYA BIOSCIENCES Corporate Presentation January 2025
Slide 2: This Presentation is not an Offer or a Representation
This Presentation is not an Offer or a Representation. This Presentation does not constitute an offer, or a solicitation of an offer, to buy or sell any securities, investment or other specific product, or a solicitation of any vote or approval, nor shall there be any sale of securities, investment
Slide 3: NAYA Biosciences: A Life-Science Portfolio Company Poised for Accelerated Growth
NAYA Biosciences (NASDAQ:NAYA) A Life-Science Portfolio Company Poised for Accelerated Growth & Value Creation Expanded, NASDAQ-listed company formed through E merger with INVO Bioscience. PgiwOendNAy, | are now Validated hub & spoke model supports acquisition, development, and partnering of high-po
Slide 4: Hub & Spoke Model Leverages Shared Resources, Leadership, & Access to Capital
Hub & Spoke Model Leverages Shared Resources, Leadership, & Access to Capital Enables Rapid Acquisition, Development, and Partnering of Assets NAYA BIOSCIENCES NASDAQ: NAYA NAYA NAYA Lees | baz | WheNee\ NAYA feoceetes —— akathlant popes Rana fa NAYA FRANCHISE TRANChISe FRANCHISES PDIxVEGF _CD38xNKp
Slide 5: Promising Therapeutic Portfolio with 2025-2027 Clinical Milestones
Promising Therapeutic Portfolio with 2025-2027 Clinical Milestones Validation of Data at Major Oncology Meetings including AACR, ASH, EHA, ESMO, and SITC ] tee | prea nor | candte | tnton | rectnit | inoEnsbing | coe Fioesk Hepatocellular Bifunctional Antibody — Carcinoma Flex-NK™ Solid & Bifunction
Slide 6: Companies Engaged in the Development of Bifunctional Antibody Therapeutics
Companies Engaged in the Development of Bifunctional Antibody Therapeutics @= oT Qs ane BIOTHEUS Merus Y JANUX BICARA ‘*Source: Bloomberg, Market Gap based on 12/51/28 Clos ‘#8 based on Glycomimetios-Creecent post-maney merger ratio of 5: Glycomimeties losing price of of $0.26 from 12/3/24 ‘(hyperti
Slide 7: Seasoned Entrepreneurial Leadership Team
Seasoned Entrepreneurial Leadership Team 8 §& Steven Shum Danie Teper PharmD, MBA ‘Anrea Goren, MBA Patrick Tol, PharmD, MBA Chis ecutive Officer President hie Financ Ofer Chie Busines Ofer ene net mre @ 3, Qwo: oso soon sign 3% LynFaleonio ‘Anna-Baran Djokovie LM Armin Rath, PHD Ravi Kiron, PhD Vil
Slide 8: Senior Advisors To Accelerate Strategic Growth
Senior Advisors To Accelerate Strategic Growth | Strategic Advisors | Laurent Auoly, Prakash Raman, Gites Seow, veep ahusinevi, eontavirin nha Pi Pio Pharm Ds. MBA MPH @ Wi . Oreo Shire — og are LU, Petite oe © Sr ° Ree € 3 “S. 3 5 y ich Cg Mo Landen M0,eh0 Josep ot MOP Yorotan MO sean PRO Bcity: Mo
Slide 9: NAYA Therapeutics: Solid Tumors Franchise
NAYA THERAPEUTICS Solid Tumors Franchise
Slide 10: HCC: A Highly Prevalent Cancer Globally with Limited Therapeutic Options
HCC: A Highly Prevalent Cancer Globally with Limited Therapeutic Options Large Adressable Market for Systemic Therapy 2000 ©2020» 2040 Rapid Increase in Liver Cancer Incidence* “Immune Checkpoint Inhibitors n Hepatocellular Carcinoma: Current Strategies and Biomarkers Predicting Response andor Resis
Slide 11: Rapidly-Evolving HCC Treatments Favor Combination Therapy & Bifunctional Antibodies
Rapidly-Evolving HCC Treatments Favor Combination Therapy & Bifunctional Antibodies High Unmet Medical Need for 70% of Non/Partial Responders Despite Significant Advances with New Standard of Care (Atezo-Bev) 2007 2017 2020 2022 2028* [ Tkis Anti-PD1s Anti-PDL1 ) | Anti-PD1 ) PD1x VEGF (sorafenib) (
Slide 12: NAYA Positioned to be a Leading Player in HCC by 2028
NAYA Positioned to be a Leading Player in HCC by 2028 with Next-Generation NY-303 & NY-500 Bifunctional Antibodies NY-500 PD1 x VEGF Flex Bifunctional Antibody Next-Generation First-Line Immunotherapy as an Alternative to Current Standard of Care (Tecentriq + Avastin™) (immune checkpoint) & VEGF (re
Slide 13: Targeting HCC with GPC3 & NK Cells with NKp46
Targeting HCC with GPC3S & NK Cells with NKp46 GPC3*: A Promising Target Glypican 3 (GPC3) is an oncofetal protein expressed on 80% of HCC cells & 30-50% of other solid tumors, while predominantly absent in normal adult tissue. GPC3 blood levels correlate with severity of HCC NKp46**: A Preferred NK
Slide 14: NY-303 Pre-Clinical Proof of Concept & Unique Reversal of NK-Cell Dysfunction
NY-303 Pre-Clinical Proof of Concept & Unique Reversal of NK-Cell Dysfunction Immune Synapse: \ / PNK Paling round ». Taw oH see, jet i= ped ae ue 6! ie 7 a ho e Teese. thaeaan!) won Teh In Vitro In Vivo Reversal of NK Cell \ Killing Assay Tumor Model Dysfunction \ Kp ULI, Rath A, ef 2, Journal for
Slide 15: NY-303 Turns "Cold" Tumors "Hot" by Reducing Active B-Catenin Levels
NY-303 Turns “Cold* Tumors “Hot” by Reducing Active B-Catenin Levels > GPC3 Makes HCC Tumors “Cold” (Non-Susceptible for Immunotherapy) Reduced B -Catenin Levels > By Reducing Reduced B -Catenin Level, NY-303 Makes them “Hot” (Susceptible), pod Facilitating Immune Cell Infiltration in Tumor Microenv
Slide 16: NY-303 Enables Response in First-Line Therapy (PD-1 Checkpoint) Refractory Patients
NY-303 Enables Response in First-Line Therapy (PD-1 Checkpoint) Refractory Patients NY-303 Down-Modulates GPCS by Inhibiting AFP & Making the Tumor Susceptible by Inhibiting f-Catenin NY-303 AFP Reduction "= cp1_opes Wm Gp2_PaNK + 196 (10m9/K9) mE GP3_PENK + CYT309 (2mg/kg) EI _GP4_PONK + CYTI03 (am
Slide 17: Ability to Redirect NK Cells to Kill HCC Tumors Cells
Ability to Redirect NK Cells to Kill HCC Tumors Cells Enhanced Killing Ability & Reversed Dysfunction of NK Cells Improved Tumor Growth Inhibition & Dose-Response in HCC Tumor Models. Turning “Cold” (Non-Susceptible) Tumors Into “Hot” (Susceptible) Tumors, Facilitating Invasion of Immune Cells to Tu
Slide 18: Targeting GPC3 to Enable Response in Patients Refractory to First Line Immunotherapy
Targeting GPC3 to Enable Response in Patients Refractory to First Line Immunotherapy HCC Treatment (Tecentrig® + Avastin®) Tecentriq® + Avastin Checkpoint Non-Responders oo seoronn gos om reese bos Tecentriq® + Avastin Checkpoint Responders ‘TeoTettow . orcenen Mn -12050-29 sna rz0geag i nme 0 vent
Slide 19: Phase I/IIa to Evaluate NY-303 as Monotherapy in 2nd Line HCC Patients
Phase I/Ila to Evaluate NY-303 as Monotherapy in 2nd Line HCC Patients at Leading Israeli Academic Centers, with Phase 2a Expansion Planned in the US, EU, and Asia Hadassah Hospital, Jerusalem ‘Sheba Medical Center, Tel Aviv Sourasky Medical Center, Tel Aviv Initiation of phase I/Ila clinical trials
Slide 20: NAYA's AI-Optimized PD1 x VEGF Bifunctional Antibody Aiming for HCC Monotherapy Readouts in 2026
NAYA’s Al-Optimized PD1 x VEGF Bifunctional Antibody Aiming for HCC Monotherapy Clinical Readouts in 2026 PD1x VEGF Bifunctional Antibodies Expected to Surpass Standard Anti-PD(L)4 Antibodies in Multiple Oncology Indications Large Market $58B Forecasted Value of 2025 PD(L)1 Market* $27.2B Keytruda ®
Slide 21: First PD1 x VEGF Bifunctional Antibody Demonstrates Progression-Free Survival Benefit
First PD1 x VEGF Bifunctional Antibody Demonstrates Progression-Free Survival Benefit Over First-Line Immunotherapy (Keytruda®) in Lung Cancer Immune Checkpoint Breakthrough Data PD1 x VEGF Bifunctional Breakthrough Data PD-{L)1 inhibitors have significantly prolonged survival shifting 1L treatment
Slide 22: NAYA Therapeutics: Immunotherapy Franchise
NAYA THERAPEUTICS Immunotherapy Franchise 23
Slide 23: NY-338: A Promising CD38-Targeting Bifunctional Antibody
NY-338: A Promising CD38-Targeting Bifunctional Antibody for Both Multiple Myeloma & Autoimmune Diseases Continued Growth of Multiple Myeloma Market Driven by Darzalex® & Biologics 2023 2030 tien = $23B— $33B Cane $9.7B $14.78 “httpsiuoufiercepharma.com/marketng/analysts-predict-myeloma-market wl hi
Slide 24: NY-338 Has Overlapping + Distinct Epitope Binding Sites Compared to Daratumumab
NY-338 Has Overlapping + Distinct Epitope Binding Sites and Gene Expression Profiles Compared to Daratumumab Differentiated Epitope Binding Sites (On) C038 mAb onde @ IB SKRNIQFSCKNIYR EKVQTLEAWVINGG cell membrane Differentiated Gene Expression Profiles «» Pathways Genes Dare Inn GZMK + + immunity a
Slide 25: NY-338 Pre-Clinical Proof of Concept & Unique Reversal of NK Cell Dysfunction
NY-338 Pre-Clinical Proof of Concept & Unique Reversal of NK Cell Dysfunction Immune Synapse: i i z In itr Kiling Assay In Vivo tumor model njo-a- O90 ‘rounds of kiling assays jm, wenn eee e a Ue eu i: ath Toe) Lin L Chang H-M, Nakid C, Frankel 8, Wu D, Kadouche J, e¢ a. P642: NOVEL MULTIFUNCTIONAL.
Slide 26: NY-338 Demonstrates Improved Profile Compared to Daratumumab
NY-338 Demonstrates Improved Profile Compared to Daratumumab 1 betes coo Meas wy Monnet “= Daratumuab : - i]t minim : | Sas “+ higst el * 2 CMD I my Beals oy Tels = “i iy Antibody Cone. (ygimL) UE IT * NY-303 shows significant lower-to-no NK fratricide compared to Daratumumab « NY-303 shows lower im
Slide 27: Proposed Mechanism of Action for NY-338's Differentiated Profile vs. Daratumumab
Proposed Mechanism of Action for NY-338’s Differentiated Profile vs. Daratumumab NY-338 Showed Lower Fratricide, Immune Subset Depletion, and Cytokine Release > NY-338 engagement of NK cells activates NKp46 signaling and neutralizes CD38-mediated apoptosis and ADCC of NK cells. > NY-338 co-engagemen
Slide 28: NY-338 Has Potential to Emerge as New Option in Multiple B-Cell Autoimmune Diseases
NY-338 Has Potential to Emerge as New Option in Multiple B-Cell Autoimmune Diseases Validated B-Cell Approach Therapeutics Approved in Rheumatoid Arthritis & Systemic Lupus Erythematous (Rituximab™, Belimumab™, Anifrolumab™) CD38 Biology Highly-Differentiated from CD19 & BCMA-Targeted approaches CD3
Slide 29: Investment Considerations
NAYA BIOSCIENCES Investment Considerations 30
Slide 30: Multiple Anticipated Clinical Milestones in 2025-2027
Multiple Anti ipated Clinical Milestones in 2025-2027 NY-303 GPC3 x NKp46 force NY-500 PD1x VEGF for Hee NY-338 (038 x NKp46 {for Multiple Myeloma NY-338 (038 x NKp46 {for Autoimmune Diseases 2025 2026 2027 FP! Phase 1/2a_ Data FPI Phase 2B IND-enabling studies FPI Phase1/2a Data mw xFPI © Phase 2B
Slide 31: Achieving Competitive Product Profiles with Bifunctional Antibodies in 2025-27
Achieving Competitive Product Profiles with 4 Bifunctional Antibodies in 2025-27 GPC3 x NKp46 PD1 x VEGF CD38 x NKp46 PSMA x NKp46 Bifunctional Antibody Bifunctional Antibody Bifunctional Antibody Bifunctional Antibody 2nd-Lne Monotherapy in HCC Al-Optimized, US-Developed Potential for Differentiati
Slide 32: NAYA Biosciences: A Life-Science Portfolio Company Poised for Accelerated Growth
NAYA Biosciences (NASDAQ:NAYA) A Life-Science Portfolio Company Poised for Accelerated Growth & Value Creation MAYA Nasdoni NAYA BIOSCIENCES Nasdaq on al cyinders” Expanded, NASDAQ-listed company formed through merger with INVO Bioscience. Validated hub & spoke model supports acquisition, developmen
NAYA Biosciences — Investor Presentation (January 2025) on 6ix